Phosphodiesterase 4 inhibitors

Abstract

Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I: wherein R 1 , R 2 , and R 3 are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

1 . A compound according to Formula I: 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is alkyl having 21 to 8 carbon atoms wherein optionally one or more —CH 2 CH 2 — groups are replaced in each case by —CH═CH— or —C≡C— groups,
 alkyl having 2 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, or 
 tetrahydrofuranyl; 
 
 R 2  is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen; 
 R 3  is —CHR 7 CONR 6 R 5  or —CHR 7 CONHR 5 ; 
 R 5  is
 aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, carboxamide, aminosulphonyl, aryl which is optionally substituted by alkyl or alkoxy, arylalkyl which is optionally substituted by alkyl or alkoxy, aryloxyalkyl wherein the aryl portion is optionally substituted by alkyl or alkoxy, arylsulfonyl, anilino, heterocycle, heterocyclic-alkyl wherein the alkyl portion is optionally substituted by oxo, or combinations thereof, or 
 a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; 
 
 R 6  is H,
 alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, or 
 alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 
 R 7  is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups,
 alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof, or 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof; 
 or a pharmaceutically acceptable salt or solvate thereof, or a solvate of pharmaceutically acceptable salt thereof. 
 
 
   
   
       2 . A compound according to  claim 1 , wherein R 7  is alkyl, and R 5  is a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by C 1-8  alkyl. 
   
   
       3 . A compound according to  claim 2 , wherein R 6  is C 1-8  alkyl or C 4-16  cycloalkylalkyl. 
   
   
       4 . A compound according to Formula I: 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is ethyl, isopropyl, cyclopropylmethyl, cyclobutylmethyl, tetrahydrofuranyl or benzyl; 
 R 2  is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen; 
 R 3  is —CH 2 CONR 6 R 5 , —CH 2 CONHR 5 , —CHR 6 CONR 6 R 5  or —CHR 7 CONHR 5 ; 
 R 5  is
 aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, carboxamide, aminosulphonyl, aryl which is optionally substituted by alkyl or alkoxy, arylalkyl which is optionally substituted by alkyl or alkoxy, aryloxyalkyl wherein the aryl portion is optionally substituted by alkyl or alkoxy, arylsulfonyl, anilino, heterocycle, heterocyclic-alkyl wherein the alkyl portion is optionally substituted by oxo, or combinations thereof, or 
 a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; 
 
 R 6  is H,
 alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, or 
 alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups 
 
 R 7  is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH—CH— or —C≡C— groups, alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —CA-C— groups,
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof, or 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof; 
 or a pharmaceutically acceptable salt or solvate thereof, or a solvate of pharmaceutically acceptable salt thereof. 
 
 
   
   
       5 . A compound according to  claim 4 , wherein R 3  is —CH 2 CONR 6 R 5  or —CH 2 CONHR 5 . 
   
   
       6 . A compound according to  claim 5 , wherein R 1  is —CH 2 CONR 6 R 5  and R 5  is a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom which is unsubstituted or substituted one or more times by halogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, carboxamide, aminosulphonyl, aryl which is optionally substituted by alkyl or alkoxy, arylalkyl which is optionally substituted by alkyl or alkoxy, aryloxyalkyl wherein the aryl portion is optionally substituted by alkyl or alkoxy, arylsulfonyl, anilino, heterocycle, heterocyclic-alkyl wherein the alkyl portion is optionally substituted by oxo, or combinations thereof. 
   
   
       7 . A compound according to  claim 6 , wherein R 6  is H or methyl. 
   
   
       8 . A compound according to  claim 6 , wherein R 5  is a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom which is unsubstituted or substituted one or more times by halogen, C 1-8 -alkyl, C 3-8 -cycloalkyl, C 4-16 -cycloalkylalkyl, C 1-8 -alkoxy, C 2-8 -alkoxyalkyl, cyano, C 1-8 -halogenated alkyl, C 1-8 -halogenated alkoxy, nitro, oxo, amino, C 1-8 -alkylamino, dialkylamino, carboxamide, aminosulphonyl, C 6-14 -aryl which is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -aryl-C 1-8 -alkyl which is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -aryloxy-C 1-8 -alkyl wherein the aryl portion is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -arylsulfonyl, anilino, heterocycle, heterocyclic-C 1-8 -alkyl wherein the alkyl portion is optionally substituted by oxo, or combinations thereof. 
   
   
       9 . A compound according to  claim 8 , wherein R 6  is H. 
   
   
       10 . A compound according to  claim 8 , wherein R 5  is a heterocyclic group which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom which is substituted one or more times by carboxamide, C 6-14 -aryl-C 1-8 -alkyl which is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -aryloxy-C 1-8 -alkyl wherein the aryl portion is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -arylsulfonyl, or anilino. 
   
   
       11 . A compound according to  claim 10 , wherein R 6  is H or methyl. 
   
   
       12 . A compound according to  claim 6 , wherein R 5  is 1,2,4-thiadiazolyl, 1,3,4-thiadizaolyl, isoxazolyl, pyrazolyl, pyrazinyl, isothiazolyl, or 1,3-thiazolyl, which is unsubstituted or substituted one or more times by halogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, carboxamide, aminosulphonyl, aryl which is optionally substituted by alkyl or alkoxy, arylalkyl which is optionally substituted by alkyl or alkoxy, aryloxyalkyl wherein the aryl portion is optionally substituted by alkyl or alkoxy, arylsulfonyl, anilino, heterocycle, heterocyclic-alkyl wherein the alkyl portion is optionally substituted by oxo, or combinations thereof. 
   
   
       13 . A compound according to  claim 12 , wherein R 6  is H or methyl. 
   
   
       14 . A compound according to  claim 12 , wherein R 5  is 1,2,4-thiadiazolyl, 1,3,4-thiadizaolyl, isoxazolyl, pyrazolyl, pyrazinyl, isothiazolyl, or 1,3-thiazolyl, which is unsubstituted or substituted one or more times by halogen, C 1-8 -alkyl, C 3-8 -cycloalkyl, C 4-16 -cycloalkylalkyl, C 1-8 -alkoxy, C 2-8 -alkoxyalkyl, cyano, C 1-8 -halogenated alkyl, C 1-8 -halogenated alkoxy, nitro, oxo, amino, C 1-8 -alkylamino, dialkylamino, carboxamide, aminosulphonyl, C 6-14 -aryl which is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -aryl-C 1-8 -alkyl which is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -aryloxy-C 1-8 -alkyl wherein the aryl portion is optionally substituted by C 1-8 -alkyl or C 1-8 -alkoxy, C 6-14 -arylsulfonyl, anilino, heterocycle, heterocyclic-C 1-8 -alkyl wherein the alkyl portion is optionally substituted by oxo, or combinations thereof. 
   
   
       15 . A compound according to  claim 14 , wherein R 6  is H or methyl. 
   
   
       16 . A compound according to  claim 4 , wherein R 3  is —CHR 7 CONR 6 R 5  or —CHR 7 CONHR 5 . 
   
   
       17 . A compound according to  claim 1 , wherein R 5  is phenyl, 1,2,4-thiadiazolyl, 1,3,4-thiadizaolyl, isoxazolyl, pyrazolyl, pyrazinyl, isothiazolyl, 1,3-thiazolyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, or 1,3-benzothiazolyl, which in each case is unsubstituted or substituted. 
   
   
       18 . A compound according to  claim 17 , wherein R 5  is 1,2,4-thiadiazolyl, 1,3,4-thiadizaolyl, isoxazolyl, pyrazolyl, pyrazinyl, isothiazolyl, 1,3-thiazolyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, or 1,3-benzothiazolyl, which in each case is unsubstituted or substituted. 
   
   
       19 . A compound according to  claim 17 , wherein R 6  is C 1-4  alkyl, R 2  is C 1-4  alkyl or halogenated C 1-4  alkyl, and R 1  is C 2-4  alkyl, cyclopropylmethyl, cyclobutylmethyl, tetrahydrofuranyl or benzyl. 
   
   
       20 . (canceled) 
   
   
       21 . A compound according to  claim 4 , wherein R 2  is CH 3  or CHF 2 . 
   
   
       22 . A compound according to  claim 4 , wherein R 1  is ethyl, isopropyl, cyclopropylmethyl, tetrahydrofuranyl, or cyclobutylmethyl; R 2  is CH 3  or CHF 2 ; R 3  is —CH 2 CONR 6 R 5 , —CH 2 CONHR 5 , or —CHR 7 CONHR 5 ; R 5  is 3-isopropyl-1,2,4-thiadiazol-5-yl, 3-methyl-isothiazol-5-yl), 1,3-thiazol-2-yl, 4-cyclopropyl-1,3-thiazol-2-yl, 4-methyl-1,3-benzothiazol-2-yl, 3-methyl-1H-pyrazol-5-yl, or 5-methyl-isoxazol-3-yl; R 6  is H or CH 3 ; and R 7  is H or CH 3 . 
   
   
       23 . A compound according to Formula I: 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups,
 alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof, 
 a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, 
 aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, 
 arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof; 
 a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof, 
 
 R 2  is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen; 
 R 3  is —CH 2 CONR 6 R 5 , —CH 2 CONHR 5 , —CHR 7 CONR 6 R 5  or —CHR 7 CONHR 5 ; 
 R 5  is isoxazolyl, pyrazolyl, or pyrazinyl, which in each case is unsubstituted or substituted one or more times by halogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, carboxamide, aminosulphonyl, aryl which is optionally substituted by alkyl or alkoxy, arylalkyl which is optionally substituted by alkyl or alkoxy, aryloxyalkyl wherein the aryl portion is optionally substituted by alkyl or alkoxy, arylsulfonyl, anilino, heterocycle, heterocyclic-alkyl wherein the alkyl portion is optionally substituted by oxo, or combinations thereof; 
 R 6  is H, 
 alkyl having 1 to 12 carbon atoms wherein optionally one or more CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups,
 alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH 2 CH 2 — groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof, 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof, 
 aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof; 
 a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or 
 a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and 
 
 R 7  is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups,
 alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof, or 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof; 
 or a pharmaceutically acceptable salt or solvate thereof, or a solvate of pharmaceutically acceptable salt thereof. 
 
 
   
   
       24 . A compound according to  claim 23 , wherein R 1  is CHF 2 , ethyl, isopropyl, cyclopropylmethyl, cyclobutylmethyl, benzyl, or tetrahydrofuranyl. 
   
   
       25 . A compound according to  claim 23 , wherein R 2  is CH 3  or CHF 2 . 
   
   
       26 . (canceled) 
   
   
       27 . A compound according to  claim 23 , wherein R 3  is —CH 2 CONR 6 R 5  or —CH 2 CONHR 5 . 
   
   
       28 . (canceled) 
   
   
       29 . A compound according to Formula I: 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups,
 alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof, 
 a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, 
 aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, 
 arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof; 
 a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof, 
 
 R 2  is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen; 
 R 3  is —CH 2 CONR 6 R 5 , —CH 2 CONHR 5 , —CHR 7 CONR 6 R 5  or —CHR 7 CONHR 5 ; 
 R 5  is 3-isopropyl-1,2,4-thiadiazol-5-yl, methylisothiazolyl, cyclopropylthiazolyl, 5-cyclopropyl-1,3,4-thiadiazolyl, methylbenzothiazolyl, or methylisoxazolyl; 
 R 6  is H,
 alkyl having 1 to 12 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more —CH 2 CH 2 — groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof, 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof, 
 aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof, 
 arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted preferably in the aryl portion, one or more times by halogen, CF 3 , OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof; 
 a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or 
 a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and 
 
 R 7  is alkyl having 1 to 8 carbon atoms wherein optionally one or more —CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups,
 alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more CH 2 CH 2 -groups are replaced in each case by —CH═CH— or —C≡C— groups, 
 cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof, or 
 cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof; 
 or a pharmaceutically acceptable salt or solvate thereof, or a solvate of pharmaceutically acceptable salt thereof. 
 
 
   
   
       30 . A compound according to  claim 29 , wherein R 1  is CHF 2 , ethyl, isopropyl, cyclopropylmethyl, cyclobutylmethyl, benzyl, or tetrahydrofuranyl. 
   
   
       31 . A compound according to  claim 29 , wherein R 2  is CH 3  or CHF 2 . 
   
   
       32 . (canceled) 
   
   
       33 . A compound according to  claim 29 , wherein R 3  is —CH 2 CONR 6 R 5  or —CH 2 CONHR 5 . 
   
   
       34 . (canceled) 
   
   
       35 . A compound selected from: 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-1,3,4-thiadiazol-2-ylacetamide, 
     N-[5-(2-furyl)-1,3,4-thiadiazol-2-yl]-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-[5-(2-piperidin-1-ylethyl)-1,3,4-thiadiazol-2-yl]acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-phenyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)acetamide, 
     N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((S)-4-{4-Methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-(5-(1-tert-butyloxycarbonylpiperidin)-4-yl-[1,3,4]thiadiazol-2-yl)-acetamide; 
     2-((S)-4-{4-Methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-(3-methyl-isothiazol-5-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-methylisoxazol-3-yl)acetamide, 
     N-Isoxazol-3-yl-2-((S)-4-{4-methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methyl-1H-pyrazol-5-yl)acetamide, 
     N-(4-Benzenesulfonyl-thiophen-3-yl)-2-((S)-4-{4-methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-acetamide, 
     2-((S)-4-{4-Methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-ppyrrolidin-1-yl)-N-(1H-pyrazol-3-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)acetamide, 
     N-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     5-{[((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetyl]amino}-3-methylisoxazole-4-carboxamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methylisoxazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-methyl-3-phenylisoxazol-4-yl)acetamide, 
     N-(3,5-dimethylisoxazol-4-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-pyrazin-2-ylacetamide, 
     N-(2-Ethyl-2H-pyrazol-3-yl)-2-((S)-4-{4-methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-phenylisoxazol-5-yl)acetamide, 
     N-(3-anilino-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{(4R)-4-[3-(benzyloxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(benzyloxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     N-(3-cyano-2-thienyl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-[4-(2-thienyl)-1,3-thiazol-2-yl]acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-(3-methylisothiazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     (4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-methyl-1H-pyrazol-3-yl)acetamide, 
     (4R)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (4S)-4-{4-(difluoromethoxy)-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}pyrrolidin-2-one, 
     (4R)-4-{4-(difluoromethoxy)-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}pyrrolidin-2-one, 
     (4S)-4-[3-(cyclobutylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (4R)-4-[3-(cyclobutylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(6-methylpyridin-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisoxazol-5-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     2-((4S)-4-{4-Methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-phenylacetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-methylisoxazol-3-yl)acetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(6-methylpyridin-2-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)acetamide, 
     N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methylacetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     N-(1-benzyl-3-methyl-1H-pyrazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-methylisoxazol-3-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     2-{(4R)-4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-methylisoxazol-3-yl)acetamide, 
     2-{(4R)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     N-ethyl-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     N-(cyclopropylmethyl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     N-(cyclopropylmethyl)-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{(4R)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{(4R)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     N-(cyclopropylmethyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(cyclopropylmethyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(cyclopropylmethyl)-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     N-(cyclopropylmethyl)-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     N-(4-cyclopropyl-1,3-thiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{(4R)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     (4R)-4-[3-(benzyloxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (4S)-4-[3-(benzyloxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (2R)-2-{(4S)-4-[3-(benzyloxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)propanamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(6-methylpyridin-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-1,3-thiazol-2-ylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-methylisoxazol-3-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(5-methylisoxazol-3-yl)acetamide, 
     (4R)-4-[4-(difluoromethoxy)-3-methoxyphenyl]pyrrolidin-2-one, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)-N-methylacetamide, and
 and pharmaceutically acceptable salts thereof, solvates thereof, and solvates of pharmaceutically acceptable salts thereof, 
 wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer. 
 
   
   
       36 . A compound according to  claim 35 , wherein said compound is selected from: 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-1,3,4-thiadiazol-2-ylacetamide, 
     N-[5-(2-furyl)-1,3,4-thiadiazol-2-yl]-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-[5-(2-piperidin-1-ylethyl)-1,3,4-thiadiazol-2-yl]acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-phenyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)acetamide, 
     N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((S)-4-{4-Methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-(3-methyl-isothiazol-5-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-methylisoxazol-3-yl)acetamide, 
     N-Isoxazol-3-yl-2-((S)-4-{4-methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methyl-1H-pyrazol-5-yl)acetamide, 
     N-(4-Benzenesulfonyl-thiophen-3-yl)-2-((S)-4-{4-methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-acetamide, 
     2-((S)-4-{4-Methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-ppyrrolidin-1-yl)-N-(1H-pyrazol-3-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)acetamide, 
     N-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     5-{[((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetyl]amino}-3-methylisoxazole-4-carboxamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-methylisoxazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(5-methyl-3-phenylisoxazol-4-yl)acetamide, 
     N-(3,5-dimethylisoxazol-4-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-pyrazin-2-ylacetamide, 
     N-(2-Ethyl-2H-pyrazol-3-yl)-2-((S)-4-{4-methoxy-3-[(R)-(tetrahydrofuran-3-yl)oxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(3-phenylisoxazol-5-yl)acetamide, 
     N-(3-anilino-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{(4R)-4-[3-(benzyloxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(benzyloxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     N-(3-cyano-2-thienyl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-[4-(2-thienyl)-1,3-thiazol-2-yl]acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-(3-methylisothiazol-5-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     (4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-methyl-1H-pyrazol-3-yl)acetamide, 
     (4R)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (4S)-4-{4-(difluoromethoxy)-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}pyrrolidin-2-one, 
     (4R)-4-{4-(difluoromethoxy)-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}pyrrolidin-2-one, 
     (4S)-4-[3-(cyclobutylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (4R)-4-[3-(cyclobutylmethoxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(6-methylpyridin-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisoxazol-5-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)acetamide, 
     2-((4S)-4-{4-Methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-phenylacetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-methylisoxazol-3-yl)acetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(6-methylpyridin-2-yl)acetamide, 
     2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methyl-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)acetamide, 
     N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methylacetamide, 
     2-{4-[3-(cyclobutylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     N-(1-benzyl-3-methyl-1H-pyrazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-methylacetamide, 
     N-ethyl-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     N-(cyclopropylmethyl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)-N-(4-methyl-1,3-thiazol-2-yl)acetamide, and 
     N-(cyclopropylmethyl)-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide,
 and pharmaceutically acceptable salts thereof, solvates thereof, and solvates of pharmaceutically acceptable salts thereof, 
 wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer. 
 
   
   
       37 . A compound according to  claim 35 , wherein said compound is selected from: 
     N-(cyclopropylmethyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(cyclopropylmethyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(cyclopropylmethyl)-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     N-(cyclopropylmethyl)-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     N-(4-cyclopropyl-1,3-thiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{(4R)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     (4R)-4-[3-(benzyloxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (4S)-4-[3-(benzyloxy)-4-(difluoromethoxy)phenyl]pyrrolidin-2-one, 
     (2R)-2-{(4S)-4-[3-(benzyloxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)propanamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(6-methylpyridin-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)meth ethoxyphenyl]-2-oxopyrrolidin-1-yl}-N-1,3-thiazol-2-ylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(5-methylisoxazol-3-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)-N-methylacetamide,
 and pharmaceutically acceptable salts thereof, solvates thereof, and solvates of pharmaceutically acceptable salts thereof, 
 wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer. 
 
   
   
       38 . A compound according to  claim 35 , wherein said compound is selected from: 
     N-(cyclopropylmethyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(cyclopropylmethyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(cyclopropylmethyl)-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(4-methyl-1,3-thiazol-2-yl)acetamide, 
     2-{4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     N-(cyclopropylmethyl)-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     N-(4-cyclopropyl-1,3-thiazol-2-yl)-2-((4S)-4-{4-methoxy-3-[(3R)-tetrahydrofuran-3-yloxy]phenyl}-2-oxopyrrolidin-1-yl)acetamide, 
     (2R)-2-{(4S)-4-[3-(benzyloxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-methylisothiazol-5-yl)propanamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)acetamide, 
     2-1{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(6-methylpyridin-2-yl)acetamide, 
     2-1{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-1,3-thiazol-2-ylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-2-oxopyrrolidin-1-yl}-N-methyl-N-(5-methylisoxazol-3-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-isopropyl-1,2,4-thiadiazol-5-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)-N-methylacetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(3-fluorophenyl)acetamide, 
     2-{(4S)-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-(4-cyclopropyl-1,3-thiazol-2-yl)-N-methylacetamide, and
 and pharmaceutically acceptable salts thereof, solvates thereof, and solvates of pharmaceutically acceptable salts thereof, 
 wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer. 
 
   
   
       39 . A pharmaceutical composition comprising a compound of  claim 4  and a pharmaceutically acceptable carrier. 
   
   
       40 . (canceled) 
   
   
       41 . A method for enhancing cognition in a patient comprising administering to said patient an effective amount of a compound according to  claim 4 . 
   
   
       42 . (canceled) 
   
   
       43 . (canceled) 
   
   
       44 . A method of  claim 41 , wherein the patient is suffering from cognition impairment or decline. 
   
   
       45 . A method according to  claim 41 , wherein said patient is suffering from memory impairment. 
   
   
       46 . A method according to  claim 45 , wherein said patient is suffering from memory impairment due to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, HIV, cardiovascular disease, head trauma or age-related cognitive decline. 
   
   
       47 . (canceled) 
   
   
       48 . (canceled) 
   
   
       49 . (canceled) 
   
   
       50 . (canceled) 
   
   
       51 . (canceled) 
   
   
       52 . (canceled) 
   
   
       53 . A method of treating a patient suffering from an allergic or inflammatory disease comprising administering to said patient an effective amount of a compound according to  claim 4 . 
   
   
       54 . (canceled) 
   
   
       55 . (canceled) 
   
   
       56 . (canceled)